logo
Global start-up ecosystem value down, but AI-native start-ups on the rise

Global start-up ecosystem value down, but AI-native start-ups on the rise

Yahoo16-06-2025
The global economy still cannot shake off the pandemic downturn, and that includes start-up ecosystems, according to the Global Startup Ecosystem Ranking 2025.
However, the authors draw a comparison between the current phase of AI integration into the global economy and the early days of internet adoption. They note that the key difference is that the current rate of AI growth is exponentially higher.
Early-stage funding deals and values have fallen dramatically since the early days of the pandemic. In the second half of 2021 (H2 2021), there were 13,215 deals valued at more than $60bn. By H2 2024, there was a fraction of this activity, with 5,391 deals valued at just over $20bn.
The report also measures a decrease in ecosystem value, which it calculates through the sum of valuations of funded start-ups plus the post-money valuation in the past two-and-a-half years. There has been a 31% ecosystem value aggregate decrease in 2025. Out of the top 20 ecosystems the report measures, only three had positive growth in this area in the past year: Beijing, Los Angeles and Tokyo.
The report emphasises the opportunities that can be created by AI native start-ups. It underlines the importance of diversifying development out of the US and China, which already receive most of the funding in the sector, so that opportunities can be created elsewhere.
JF Gauthier, founder and CEO of Startup Genome (which authors the report), highlights that, currently, most AI budgets are being spent on infrastructure, research, and adoption of "existing AI solutions developed in the US and China". This means that entrepreneurial AI policy, the "engine of local job creation", according to Gauthier, is being overlooked.
"Governments and agency leaders in charge of start-up ecosystems have, in this critical moment, the most important job of steering their societies to invest locally to produce long-term prosperity. Instead of investing 100% of the AI budget in the US and Chinese innovation – the value of which will be eroded by next year – allocate at least 25% of that investment to building your local AI-native start-up ecosystem," Gauthier advises.
This embedded content is not available in your region.
In creating the 2025 rankings, the report looked at six success factors: AI-native transition, funding, knowledge, market reach, performance, and talent and experience. It highlights South Korea's start-up policies, with the Seoul Metropolitan Government having invested $1.4bn (1.9trn won) in policies and initiatives over the past four years and therefore climbing 12 ranks. Singapore has also risen eight ranks since the mid 1990s through the pursuit of start-up-friendly policies.
This embedded content is not available in your region.
The factors weighed to rank emerging ecosystems are slightly different from those for the top locations. There is more focus on early-stage funding and less emphasis on the number of exits.
Wuxi, China, attained the top spot in the ranking following a 67% increase in exits, with values over $50m (359.03m yuan). Jakarta gained four ranks and Istanbul ten, after an increase in funding and market reach. Riyadh has had the most significant growth in the Middle East and North Africa region, jumping from the 51–60 range in 2024 to the 21–30 range in 2025. This growth was fuelled by an increase in exits of more than $50m (SR187.5m), such as Rasan's $1.1bn exit.
"Global start-up ecosystem value down, but AI-native start-ups on the rise – report" was originally created and published by Investment Monitor, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Russian rouble, stock market gain after Trump's statement on Russia
Russian rouble, stock market gain after Trump's statement on Russia

Yahoo

time30 minutes ago

  • Yahoo

Russian rouble, stock market gain after Trump's statement on Russia

MOSCOW (Reuters) -The Russian rouble reversed losses against the dollar and rose against China's yuan after U.S. President Donald Trump warned he would impose "very severe tariffs" on Russia if no deal on a peaceful settlement is made in 50 days. As of 1605 GMT, the rouble was 0.2% weaker at 78.10 per U.S. dollar after hitting 78.75 during the day, according to LSEG data based on over-the-counter quotes. The rouble is up about 45% against the dollar since the start of the year. Trump announced new weapons for Ukraine on Monday and threatened to hit buyers of Russian exports with sanctions, expressing frustration with Russian President Vladimir Putin due to the lack of progress in ending the war in Ukraine. "Trump performed below market expectations," said analyst Artyom Nikolayev from Invest Era. "He gave 50 days during which the Russian leadership can come up with something and extend the negotiation track. Moreover, Trump likes to postpone and extend such deadlines." Against the Chinese yuan, the most traded foreign currency in Russia, the rouble strengthened 0.8% to 10.87 after weakening by over 1% on Friday. The Russian stock market rose 2.7% after Trump's statement, according to the Moscow Stock Exchange.

Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Yahoo

time37 minutes ago

  • Yahoo

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Dollar Rallies on Higher T-note Yields
Dollar Rallies on Higher T-note Yields

Yahoo

time37 minutes ago

  • Yahoo

Dollar Rallies on Higher T-note Yields

The dollar index (DXY00) today is up +0.47%. The dollar is seeing support as the 10-year T-note rose +3.6 bp and the 30-year T-bond yield rose back above 5% for the first time in 1.5 months. The rise in Treasury yields supported the dollar's interest rate differentials. Today's US CPI report generated some favorable initial media coverage as the June core CPI report of +0.2% m/m was slightly below expectations of +0.3%. However, there were some scattered signs of upside pressure from tariffs, and that pressure is expected to increase in the coming months. Also, both the headline and core CPI reports on a year-over-year basis rose from May. Latest US Tariff Threats Boost the Dollar Dollar Supported by Latest US Tariff Threats Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Specifically, the June US CPI rose +0.3% m/m, which was in line with market expectations, while the year-over-year figure of +2.7% was slightly worse than expectations of +2.6% and was up from May's +2.4%. The June US core CPI rose +0.2% m/m, which was slightly better than expectations of +0.3%. On a year-over-year basis, the June US core CPI was in line with expectations at +2.9% y/y but rose from May's +2.8%. Today's CPI report did not improve market expectations for Fed easing, which were little changed after the CPI report. Federal funds futures prices are discounting the chances for a -25 bp rate cut at 3% at the July 29-30 FOMC meeting and at 65% at the following meeting on Sep 16-17. There was some positive trade news today after Treasury Secretary Bessent said that US-China trade talks are in a "very good place," which reduced safe-haven demand for the dollar. He also said the US-China deadline is flexible and told market participants "not to worry about August 12." Mr. Bessent confirmed that the Trump administration has told Nvidia that a license for the sale of its advanced H20 GPU chips to Chinese firms will be granted and is "all part of a mosaic" in the US-China negotiations. He also said he hopes to meet with Chinese Vice Premier He Lifeng in August. EUR/USD (^EURUSD) is down -0.36% on strength in the dollar. The euro was also undercut by today's -2.4 bp decline in the 10-year bund yield, which reduced the euro's interest rate differentials. The euro saw underlying support from news that the July German ZEW expectations index rose +5.2 points to 52.7 from 47.5 in June, which was stronger than expectations for an increase to 50.4. The euro also saw underlying support as the May Eurozone industrial production report of +1.7% m/m and +3.7% y/y was stronger than market expectations of +1.0% m/m and +2.2% y/y. Swaps are pricing in a 2% chance of a -25 bp rate cut by the ECB at the July 24 policy meeting. USD/JPY (^USDJPY) is up +0.76% on dollar strength. Additionally, the yen remains under pressure due to concerns about the upcoming upper house election in Japan on July 20. The promises by Japan's ruling Liberal Democratic Party of cash handouts to voters and promises of lower taxes by the opposition have sparked concerns of fiscal deterioration, which are bearish for the yen. August gold (GCQ25) is down -2.2 (-0.07%), and September silver (SIU25) is down -0.402 (-1.04%). Precious metals are trading lower on today's +0.47% rise in the dollar index and the +3.6 bp rise in the 10-year T-note yield. Sep silver is seeing some long liquidation after falling back from Monday's contract high. July 2025 silver today fell back from Monday's 14-year high on the nearest-futures chart. Precious metals prices also fell back today on some favorable trade news as Treasury Secretary Bessent claimed that US-Chinese trade talks were in a "very good place." On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store